MassBiologics of UMass Medical School and Voyager Therapeutics will collaborate on viral vector manufacturing at the new MassBiologics SouthCoast facility in Fall River.
At the forefront of materials research for the biomedical field, Jie Song, PhD, is using 3D printers to build scaffolding for bone repair, according to an article in the Worcester Telegram & Gazette.
Data from 11 newborn screening programs, including the New England Newborn Screening Program, showed that newborn screening for severe combined immunodeficiency can be successfully implemented across public health newborn screening programs, according to a new study published in the Aug. 20 issue of the Journal of the American Medical Association (JAMA).
In this Expert’s Corner video, Craig J. Ceol, PhD, explains how he is using the zebrafish to identify the genes that give rise to melanoma, the most deadly form of skin cancer.
A new study on binge drinking by Gyongyi Szabo, MD, PhD, found that a single episode of binge drinking can have significant negative health effects resulting in bacteria leaking from the gut, leading to increased levels of toxins in the blood.
The U.S. Food and Drug Administration has approved the start of a mid-stage clinical trial of an adult stem cell treatment for patients with ALS according to its developer, BrainStorm Cell Therapeutics Inc. The Phase II clinical trial will be launched initially at UMass Medical School and Massachusetts General Hospital in Boston.
MassBiologics received a $5 million grant from the Massachusetts Life Sciences Center to support construction of a viral vector manufacturing facility, the first of its kind in Massachusetts. In this video, Executive Vice Chancellor Mark Klempner explains the therapeutic potential of viral vectors and why MassBiologics was chosen to receive this grant.
News that a second baby born with HIV appears to have been cleared of infection after early and aggressive treatment is further evidence that early therapy may be the key to achieving remission, said immunologist Katherine Luzuriaga, MD, who is working on both cases.
Researchers at the UMass Medical School have been commissioned by the Alpha-1 Project to develop a PiZ antibody, an essential tool for testing potential therapies for alpha-1 antitrypsin deficiency.